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Introduction
Cancers have traditionally been classified 
clinically and pathologically based on stage 
and grade. Stage is closely associated with 
patient prognosis, generally defined as 
progression-free survival (PFS) and overall 
survival (OS). Although prognosis has been 
shown to be dependent on local tumour 
involvement, regional lymph node metastasis, 
lympho-vascular invasion, positive surgical 
margins, preoperative elevation of CEA (a 
circulating tumour marker), high tumour 
grade, and tumour budding, responses to 
treatment are still difficult to predict in 
specific scenarios, particularly the metastatic 
setting.1  
The Union of International Cancer Control 
(UICC) and American Joint Committee on 
Cancer (AJCC) Tumour Node Metastasis 
(TNM) systems are the most commonly used 
classifications for colorectal cancer staging. 
The TNM classification was developed in 
the 1940s and codes the depth of primary 
tumour (T) invasion into or beyond the 
colorectum (invasion of or adherence to 
adjacent organs or structures), the number 
of regional lymph nodes involved (N), and 
the presence or absence of distant metastasis 
(M).2  The classification allows grouping 
of these three indicators and provides a 
“stage-grouping”.3  The TNM classification is 
a dual system and comprises a clinical (pre-
treatment) classification (usually referred to 
as cTNM) and a pathological (post-surgical 
histopathological) classification (pTNM).4  
As a rule, surgical decisions are based on 
cTNM classification, while post-surgical 
management and prognosis are established 
using the pTNM classification.  
In 1932, the Dukes’ staging system was 
proposed for rectal tumours that classified 
tumours pathologically into three different 
stages: A to C.5 Dukes established that the 
extent of local tumour invasion (A – least, C- 
most) was prognostic and reliably predicted 
operative mortality. This classification was 
then adapted to colon cancer and further 
variations were introduced, namely the 
introduction of Stage D (distant metastasis) 
and the Modified Astler-Coller (MAC) 
classification.5 Today, the Dukes’ staging 
system and the MAC classification have 
been superseded by the UICC and AJCC TNM 
systems and subsequently their use is highly 
discouraged.
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Abstract
Colorectal cancer (CRC) is a heterogeneous disease with several 
clinical, pathological, and molecular presentations.  A comprehensive 
and unifying molecular classification would be useful for genotype-
phenotype correlations, to better understand disease progression, and to 
predict responses to treatment.  Such a classification would be helpful 
for quickly and efficiently translating results from the laboratory to the 
clinic and closing the gap between research breakthroughs and actually 
implementing them clinically.  In November 2015, an international 
consortium consisting of six expert groups published the first consensus 
on molecular subtypes of colorectal cancer, by bringing together six 
previously published CRC classifications.
Molecular classification 
of colorectal cancer
Educational aims
•	 To describe the current molecular markers used in colorectal cancer
•	 To give an overview of the various colorectal cancer molecular 
classifications published in the past five years
•	 To describe the first consortium colorectal cancer taxonomy
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Molecular markers currently used in 
colorectal cancer
With further advances in biomedicine, it has 
become possible to classify tumours based 
on their molecular characteristics. Three 
main cancer pathways are implicated in 
CRC molecular classification: microsatellite 
instability (MSI), chromosomal instability 
(CIN), and the CpG island methylation 
phenotype (CIMP).  MSI is characterised by 
small insertions or deletions in repetitive 
DNA sequences (microsatellites).6 When 
MSI is not present, a tumour is defined as 
microsatellite stable (MSS). CIN is defined as 
an elevated frequency of whole-chromosome 
missegregation, and CIMP occurs when there 
is methylation of the CpG islands within 
the promoter region and is associated with 
transcriptional silencing.7,8  In 2008, Ogino 
and Goel proposed a revised molecular 
classification based on the five subgroups 
proposed by Jass in 2007 that consisted of 
six subgroups: Group 1: MSI-H CIMP-High 
(10%); Group 2:  MSI-H CIMP – Low/0 (5%); 
Group 3:  MSI-L/MSS CIMP-High (5-10%); 
Group 4:  MSI-L CIMP-Low (5%); Group 5: MSS 
CIMP-Low (30 to 35%); Group 6: MSI-L/MSS 
CIMP-0 (~40%).6,9 This molecular classification 
depends on common DNA markers together 
with BRAF and KRAS mutational status.10
With the advent of high-throughput 
molecular technology, we are now generating 
a vast amount of genomic, transcriptomic, 
proteomic, and metabolomic data that are 
facilitating the comprehensive molecular 
characterisation of cancer. The aim is to 
identify a robust molecular signature that 
can be applied in the clinic and help to 
identify the best treatment and care for 
the individual. Furthermore, it would be 
helpful to establish molecular signatures 
capable of predicting individuals at higher 
risk of developing the disease who hence 
must take preventative measures (diagnostic 
biomarkers). Molecular signatures would 
also be beneficial in guiding clinicians with 
respect to predicting recurrence of the disease 
following surgery (surveillance biomarkers). 
Other beneficial molecular signatures are 
prognostic biomarkers, which give an 
indication of the likely progression of disease, 
and predictive biomarkers, which predict 
responses to treatment. This has been best 
demonstrated in breast cancer, in which the 
molecular classification has been useful for 
both diagnosis and treatment.11-14  
However, the molecular characterisation 
of colorectal cancer has lagged behind breast 
cancer in which, in some instances, diagnosis 
and treatment are based on the expression 
of particular molecules, e.g. expression 
of the estrogen receptor (ER) to indicate 
anti-estrogen therapy or amplification of 
the human epidermal growth factor receptor 
2 (HER2) for HER2-directed therapy.15 
This progress in breast cancer has in no 
small part been driven by its molecular 
classification. Nonetheless, there are still 
clinical dilemmas in CRC that would benefit 
from a molecular classification approach: a) 
who might develop metastases even though 
they have a favourable pathological stage? 
b) who needs adjuvant therapy even if there 
is no nodal involvement? c) who is likely to 
best respond to specific chemotherapy or 
targeted therapy? To this end, there have 
now been a number of efforts to develop a 
better molecular classification of colorectal 
cancer.  Over the past decade, a number of 
complex classification studies producing 
variable results have been published.   
Although the different cohorts, methods, 
group sizes, and clinical information have 
meant that these classification systems have 
seemed different, in fact there is emerging 
commonality between them.  In this brief 
review, we highlight six of the most recent 
classifications that together form the basis 
of the recently published consensus on 
molecular classification of CRC developed by 
the CRC Subtyping Consortium (CRCSC).  
Classification based on mesenchymal or 
epithelial expression signature 
In 2012, Schlicker et al. stratified and 
pharmacologically characterised a panel of 
74 different CRC cell lines.16 Furthermore, 
using iterative clustering, this analysis 
revealed five CRC subtypes (1.1, 1.2, 1.3, 
2.1, 2.2) that were successfully validated on 
over 1600 CRC tumour samples from publicly 
available gene expression datasets.  
Type 1 tumours exhibited a mesenchymal 
expression signature, had a poor prognosis, 
and similar number of MSI and MSS tumours 
(out of the annotated cohorts (n = 229), 
58 Type 1 tumours exhibited MSI and 59 
exhibited MSS).  Type 2 tumours exhibited 
an epithelial expression signature, had a 
good prognosis, and were enriched with 
MSS tumours.  Further subtyping of Type 
1 tumours revealed that subtype 1.1 was 
strongly mesenchymal, enriched in late-stage 
CRC, and the up-regulated genes were mainly 
involved in Ca-signalling and SRF-targeted. 
Moreover, subtype 1.1 was characterized 
by pathways involved in angiogenesis, 
inflammation, and proliferation. Subtype 1.2 
contained more female than male patients, 
were mostly MSI enriched, and activated 
similar pathways to 1.1 but also strongly 
activated the JAK-STAT signalling pathway. 
Furthermore, the main up-regulated genes 
were immune-system related. Subtype 1.3 
exhibited high expression of transporter genes 
and were mainly MSS.   
Additional subtyping of type 2 tumours 
resulted in two further subtypes – subtype 
2.1 and subtype 2.2. In the former, pathways 
related to inflammation, angiogenesis and 
proliferation were activated. Moreover, stress 
response and immune system-related genes 
were up-regulated. In subtype 2.2, a number 
of genes that were up-regulated were involved 
in cell cycle and amino acid synthesis. Some 
other genes up-regulated in subtype 2.2 
were located on a number of cytobands in 
chromosome 20q and 13q.   
The authors also adopted a comprehensive 
cell line model to investigate the relationship 
between the CRC subtypes and cell signalling 
and, additionally, associate the molecular 
features with drug responses. They showed 
that CRC cell lines classified as subtype 1.2 
were highly sensitive to glycogen synthase 
kinase, Src, and Wnt signalling inhibitors. On 
the other hand, CRC cell lines designated as 
type 2 when compared to those classified as 
type 1 were considerably more sensitive to 
aurora kinase inhibitors.
Classification based on CIN subtype, MSI/
CIMP positive subtype and KRAS/BRAF 
mutation subtype
In 2013, two colorectal classification papers 
were published in Nature Medicine.  In the 
first article De Sousa E Melo F et al described 
three molecularly distinct CRC subtypes (CCS1, 
CCS2 and CCS3), where one of the subtypes 
(CCS3) was characterized for the first time.17 
An integral part of this study was the analysis 
of the gene expression data of 1,164 CRC 
patients using an unsupervised classification 
strategy. All the CRC samples, xenografts, cell 
lines, and precursor lesions were classified into 
the three subtypes using a 146-gene classifier.
Colon Cancer Subtype 1 (CCS1) mainly 
consisted of chromosomal instable (CIN) 
cancers – the majority of the samples in 
this group generally had KRAS and/or TP53 
mutations.  Moreover, the tumours in this 
group were principally located on the left side 
of the colon.   From a metastasis point of 
view, the authors concluded that Wnt target 
genes were highly expressed in CCS1 and that 
they metastasize less frequently compared to 
CCS3 tumours.  
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Colon Cancer Subtype 2 (CCS2) mainly 
consisted of MSI/CIMP-positive tumours 
located on the right side of the colon. The 
authors focused principally on CCS3 since 
it was the least well characterized subtype 
and, furthermore, compared it mainly with 
CCS1 tumours; hence, there is relatively little 
information on CSS2. 
Colon Cancer Subtype 3 (CCS3) was not 
enriched with either CIN or MSI tumours 
but contained a relatively large number of 
patients with KRAS or BRAF mutations. The 
tumours were distributed throughout the 
colon and tended to be poorly differentiated. 
Based on the microsatellite stable and 
CIMP+ status, together with relative over-
representation of BRAF mutants, the authors 
hypothesised that these tumours can arise 
from pre-neoplastic lesions associated 
with the serrated pathway. This was also 
confirmed using Principal Component 
Analysis on the patient set, classifier, and 
independent cohorts. Furthermore, when 
comparing CCS1 with CCS3 using Gene Set 
Enrichment Analysis (GSEA), it appeared that 
in the CCS3 subtype the up-regulated genes 
were involved in epithelial to mesenchymal 
transition, matrix remodelling, cell 
migration, and transforming growth factor β 
signalling.  The authors concluded that the 
least characterized subtype (CCS3) is highly 
malignant when compared to CCS1 and CCS2. 
Disease-free survival (DFS) was 
statistically significantly lower in CCS3 
compared to CCS1 and CCS2 tumours. 
Furthermore, over half of the CCS3 patients 
had a recurrence within two years and, 
overall, the patients in this subgroup had 
a poorer DFS. In addition to the proposed 
classification, the authors examined the 
responses of the different subtypes to 
targeted therapy. The authors inferred that 
CCS3 metastatic colorectal cancer patients 
were resistant to cetuximab, independent of 
the KRAS mutational status. This difference 
in response was also observed in vitro when 
comparing CCS1 cell lines versus CCS3 cell 
lines.17
Classification based on intestinal  
stem cells and their respective 
differentiated cells 
In the second paper, Sadanandam et al 
described six CRC subtypes (stem-like, 
inflammatory, transit-amplifying cetuximab 
resistant, transit-amplifying cetuximab 
sensitive, goblet-like, enterocyte) together 
with their response to cetuximab, standard 
of care chemotherapy, and DFS.18 The CRC 
subtypes were generated using consensus-
based unsupervised clustering of the gene 
expression profiles of 1,290 CRC samples.   
The least differentiated stem-like sub-
type phenotype was associated with the 
base of the colon crypt and had a poor 
DFS. Patients with this subtype had higher 
expression of Wnt signalling, stem cell, 
myoepithelial, and mesenchymal genes while 
having lower expression of differentiation 
markers. This group was predicted to benefit 
from chemotherapy (preferably FOLFIRI – a 
chemotherapy regimen containing leucovorin 
calcium, 5-fluorouracil and irinotecan) – 
both as an adjuvant treatment and also in 
the metastatic setting.  
The second subtype was referred to 
as inflammatory and was not associated 
with crypt-top or base phenotypes. The 
main upregulated genes in this group were 
interferon-related and chemokines. With 
regards to treatment, it was suggested that 
patients in the adjuvant setting should 
ideally be treated with chemotherapy, more 
specifically with FOLFIRI. On the other hand, 
in the metastatic setting, both chemotherapy 
and cetuximab could be ineffective. This 
subtype also had an intermediate DFS.  
The goblet-like subtype was equated 
with the top part of the colon crypt and had 
a good DFS.  This subtype exhibited high 
mRNA expression of goblet-specific MUC2 
and TFF3. The patients in this subtype would 
possibly be unresponsive to treatment in the 
adjuvant setting and hence it was suggested 
that watchful surveillance should instead be 
implemented following surgical resection. 
On the other hand, the authors advised 
that, in the metastatic stage, chemotherapy 
(preferably FOLFIRI) or another therapy 
(that still to be determined) should be 
administered.
The enterocyte-like sub-type was 
characterized by high expression of 
enterocyte-specific genes. Patients 
assigned to this group had an intermediate 
DFS. Based on the gene signature of the 
enterocyte-like sub-type, it was determined 
that these tumours identify with the 
colon-crypt top phenotype. Furthermore, 
when compared to the stem or progenitor 
cell phenotype, the enterocyte-like sub-
type had a more differentiated phenotype. 
As a result of these association studies, 
the authors recommended that patients 
receiving adjuvant treatment in this sub-
group should be treated with chemotherapy 
(preferably FOLFIRI) or other therapy 
(excluding cetuximab or c-MET therapy). 
On the other hand, for metastatic disease, 
the authors did not recommend treatment 
with chemotherapy, cetuximab, or a c-MET 
inhibitor.
The final sub-type described was the 
transit-amplifying (TA) sub-type which, 
to a certain extent, was considered a 
heterogeneous group since both the stem 
cells and Wnt target genes were irregularly 
expressed. Furthermore, this subtype also 
exhibited a mixed phenotype, since 59% 
of these tumours had a crypt top signature 
with low expression of Wnt signalling 
targets. On the other hand, the remainder of 
the TA subtype were significantly associated 
with crypt base and over-expressed stem and 
progenitor markers such as LGR5 and ASCL2.  
In this subtype, the authors recommended 
that both adjuvant chemotherapy and 
chemoradiotherapy should be avoided, since 
they identified a trend that patients in this 
subtype had a lower DFS when treated.   
Following a series of proliferation assays 
to monitor drug responses, this subtype 
was further divided into another two sub-
subtypes – cetuximab-sensitive transit-
amplifying (CS-TA) and cetuximab-resistant 
transit-amplifying (CR-TA).  CS-TA exhibited 
statistically significant higher expression 
of EREG and AREG compared to CR-TA. 
In contrast, CR-TA demonstrated higher 
expression of filamin A, which is involved 
in c-MET regulation.  In effect, this subtype 
(CR-TA) was sensitive to in vitro treatment 
with a c-MET inhibitor. The authors hence 
concluded that, in the metastatic setting, 
CS-TA patients should be treated with 
cetuximab while CR-TA should be treated 
with a c-MET inhibitor. 
Classification based on  
clinicopathological variables and 
commonly used DNA markers
In a third paper in 2013, Marisa et 
al. published in PLoS Medicine a gene 
expression classification of six molecular 
subtypes based on clinicopathological 
variables and commonly used DNA markers.10 
The relevance of this classification is that 
the subtypes were associated with different 
prognoses. The study was performed 
using a discovery set of 443 patients 
and a validation set of 1,029 patients. 
In this classification, the subtypes were 
named in accordance with their biological 
characteristics as described below.
The first subtype C1, termed CINImmune-
Down, shared a lot of similarities with 
C5CINWntUp.  Both subtypes fell under the 
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conventional precursor neoplasia pathway, 
with very low frequencies of mismatch 
repair deficient genes (dMMR) and CIMP 
in contrast to very high frequencies of 
CIN. Furthermore, in both subtypes, the 
majority were located in the distal colon. 
With respect to mutational status, both 
C1-CINImmune-Down and C5CINWntUp exhibited 
intermediate KRAS and TP53 mutation 
frequency but very low BRAF mutation 
frequency.  When comparing resemblance 
to supervised gene expression signatures, 
both subtypes had minimal characteristics 
with BRAF mutant-like supervised signatures 
and exhibited intermediate likeness to a 
“normal-like” supervised signature.  One 
of the main differences between the two 
subtypes was that C5CINWntUp demonstrated 
an intermediate frequency of tumours with 
stem-cell phenotype-like gene expression 
profiles, while C1-CINImmune-Down exhibited 
a very low frequency. The other main 
difference between these two subtypes 
was in respect of deregulated signalling 
pathways. In C1-CINImmune-Down, most 
signalling pathways were downregulated, 
especially cell communication and immune 
pathways. On the other hand, in C5CINWntUp, 
cell communication, Wnt and metabolism 
pathways were upregulated.
The other four subtypes, namely, C2 
dMMR, C3 KRASm, C4 CSC and C6 CINnormL were 
linked to the serrated precursor neoplasia 
pathway.  The C2 dMMR subtype consisted 
mainly of dMMR (68%) and BRAF mutant 
tumours (40%) and were very frequently 
located in the proximal colon. Furthermore, 
a very high frequency of CIMP (59%) was 
recorded in this subtype.  KRAS mutant 
tumours were also found at an intermediate 
frequency. With respect to supervised gene 
expression, the majority of the C2 dMMR 
exhibited a BRAFm-like signature and a 
serrated CC-like signature. Moreover, the 
immune system and cell growth pathways 
were found to be up-regulated in this 
subtype, whilst the Wnt pathway was found 
to be deregulated.
The C3 KRASm subtype was also 
frequently located in the proximal colon 
and was mainly enriched for KRAS mutant 
tumours (87%). This subtype displayed an 
intermediate frequency of CIN+, and 18% 
of the tumour were CIMP+.  Moreover, most 
signalling pathways in C3 KRASm tumours 
were down-regulated. 
The metastasis-enriched (31%) C4-
CSC subtype was the only subtype with 
a reproducible association between poor 
prognosis and the supervised stem-cell 
gene expression signature.  This subtype 
was frequently located in the proximal 
colon, had intermediate frequency of CIN+, 
and 34% of the patients were CIMP+. 
Intermediate frequencies for KRAS and 
TP53 mutations were reported in this 
subtype. The majority of the tumours in 
this subtype (91%) exhibited the stem cell 
phenotype-like gene expression signature. 
Besides the stem cell signature, this subtype 
also displayed the BRAF-mutant like gene 
expression profile and the serrated CC-like 
signature. The EMT/motility pathways were 
up-regulated, whilst the cell growth and 
death pathways were down-regulated.  
The final subtype described in this 
study was C6 CINnormL. Although classified 
under the serrated precursor neoplasia 
category, this subtype was mainly CIN+ 
(86%), CIMP-, TP53 mutant, and located in 
the distal colon.  In contrast to the other 
CIN+ subtypes, this subtype exhibited very 
high frequencies of the normal-like gene 
expression signature and intermediate 
frequencies of the serrated CC-like gene 
expression profile.  Moreover, C6 CINnormL 
showed down-regulation of the proliferation 
pathways and upregulation of the EMT/
motility pathways.  
Finally, the authors demonstrated 
that there was a statistically significant 
association between subtypes C4-CSC and C6 
CINnormL and prognosis.   In fact, Stage II/III 
patients with one of these two subtypes had 
a worse prognosis, with 5-year relapse-free 
survival rates of 52% and 61%, respectively. 
Classification based on biological motifs, 
morphology, common clinical variables, 
and molecular markers 
In July, 2013 Budinska and colleagues 
described an additional five subgroup 
classification using a discovery set of 
1,113 CRC gene expression profiles and a 
validation set of 720 CRC transcriptomic 
profiles.19 The authors used unsupervised 
clustering of genome-wide transcriptome 
analysis and moreover, described each 
subtype with respect to biological motifs, 
morphology, common clinical variables, and 
molecular markers.  The five major subtypes 
characterized were:  A – surface crypt-like; 
B – lower crypt-like; C – CIMP-H-like; D – 
mesenchymal-like and E – mixed.  These 
subtypes do not replace classification using 
current clinicopathological variables or 
molecule markers but merely complement 
them.
The surface crypt-like subtype (A) was 
significantly enriched in KRAS-mutant 
tumours, having predominantly a papillary 
or serrated histopathology and a low 
percentage of β-catenin-positive nuclei 
at the invasive front.  The authors also 
observed that tumours in this subtype were 
well differentiated and most comparable to 
normal colonic epithelium by gene expression 
profiling.  Moreover, gene expression analysis 
showed up-regulation of genes involved in 
the top of the colonic crypt, secretory cells, 
and metallothioneins, whilst genes involved 
with EMT/stroma, Wnt, putative colon cancer 
stem cells (CSCs), Chr20q, and proliferation 
were down-regulated.  In this subtype, 
survival after relapse (SAR) was 28.9 months. 
The well-differentiated lower crypt-
like subtype (B) displayed complex tubular 
morphology and had a high percentage of 
β-catenin-positive nuclei at the invasive 
front.  A higher copy number gain/
amplification was reported in Chr20q.  
Moreover, over-expression of genes involved 
in the top of the colonic crypt, proliferation 
(mainly EREG), and Wnt pathway was 
detected in the lower crypt-like subtype.  
In contrast, gene expression regulating the 
EMT/stroma, immune system, and secretory 
cells were down-regulated.  From a clinical 
point of view, the tumours in this subtype 
were mainly located on the left side and 
were grade 2.  The SAR was the highest 
when compared to the other subtypes (50.4 
months).  Furthermore, this subtype was 
significantly prognostic with respect to RFS, 
OS, and SAR. 
Subtype C – CIMP-H-like was 
commonly MSI+ and BRAF mutant (87%) 
and histopathologically characterized 
by solid/trabecular or mucinous growth 
patterns.  Commonly, tumours falling in 
this subtype were located on the right hand 
side and were high grade. At the invasive 
front, subtype C tumours did not show 
any β-catenin nuclear immunoreactivity, 
although transcriptomically they had high 
expression of immunity-associated genes, 
metallothioneins, and homeobox gene 
module. However, this subtype had low 
expression of gut development, top colon 
crypt, EREG, Chr20q genes, and genes 
differentially expressed in the CRC (GDC) 
gene module. The CIMP-H-like subtype was 
associated with a poor OS (SAR of only 6.9 
months). The authors speculated that this 
subtype had a transcriptomic signature of a 
group of tumours that, once metastasized, 
would become resistant to chemotherapy.
Issue 22  2016 Journal of the Malta College of Pharmacy Practice          39
Histopathological examination of the 
fourth CRC subtype (mesenchymal) revealed 
a desmoplastic pattern and immunochemistry 
(IHC) showed that only a low percentage 
of β-catenin-positive nuclei were present 
at the invasive front. Among other 
upregulated gene expression signatures, this 
subtype also had a high EMT/stroma gene 
expression.  In contrast, lipid synthesis 
gene expression and the canonical Wnt 
signalling target signatures were among 
those down-regulated in the mesenchymal 
subtype. This subtype had a high frequency 
of BRAF mutant tumours and was correlated 
with poor OS, possibly as a result of the 
high EMT expression and low expression of 
proliferation-associated genes. Moreover, 
this subtype was also significantly prognostic 
with respect to RFS and SAR.    
The final subtype described in this 
study was the mixed subtype (E), which was 
mainly located on the left side of the colon. 
Histopathologically, this subtype appeared as 
complex tubular, and IHC showed that a high 
percentage of β-catenin-positive nuclei were 
present at the invasive front. Among other 
upregulated gene expression signatures, 
this subtype also had high EMT/stroma 
gene expression, canonical Wnt signalling 
pathway target signatures, EREG gene module 
expression, and homeobox gene module 
expression.  
Classification based on three biological 
hallmarks of cancer
The last classification we review was 
published in July 2013 by Roepman et 
al..20 This classification proposed three 
different intrinsic subtypes based on 
the three biological hallmarks of cancer 
– epithelial to mesenchymal transition, 
deficiency in mismatch repair genes, and 
cellular proliferation. This molecular CRC 
classification was derived by unsupervised 
clustering of multi-omic data generated from 
188 stages I – IV CRC patients (discovery 
set).  The validation set comprised of 320 
Stage II and 223 Stage III CRC patients and 
was associated with prognosis and response 
to chemotherapy.  
Thirty-five percent and 22% of patients 
were classified as MMR-deficient epithelial 
A-type in the discovery cohort and validation 
cohort, respectively. This subtype had a 
significantly higher percentage of MSI+ 
tumours (49%) and was also enriched for 
BRAF mutants. The authors speculated 
that this subtype may be more prevalent 
in early-stage cancers. Sixty-eight percent 
of the patients in this cluster exhibited an 
MSI/dMMR expression profile.  Differential 
gene expression analysis for mesenchymal 
and epithelial markers revealed that A-type 
tumours could be deemed epithelial. From 
a proliferative point of view, this subtype 
exhibited the highest expression of MKI67. 
When compared to the other two subtypes, 
the prognosis for A-type-MSI patients 
was very good (93% with 10-year distant 
metastasis-free survival). Response to 
chemotherapy was assessed in 222 Stage III 
patients, where patients in this group had a 
better OS from adjuvant chemotherapy with a 
hazard ratio (HR) of 0.39 (p = 0.18).    
The proliferative epithelial-like B subtype 
consisted of 52% of the discovery cohort 
patients and 62% of the validation cohort 
patients. This subtype encompassed mainly 
BRAF wild-type tumours (98%) and was 
almost entirely MSS and pMMR phenotype 
(99%). In this group, CDH2, FGFR1, and 
TGFB1 (mesenchymal markers) were down-
regulated, while four epithelial markers were 
up-regulated. This subtype was characterized 
as highly proliferative as a result of up-
regulation of MKI67 and even stronger 
with respect to AURKA. These patients had 
a relatively poor baseline prognosis but 
patients in this category would be expected 
to benefit from adjuvant chemotherapy with 
5-fluorouracil (5-FU) (HR = 0.42, p = 0.014).
The mesenchymal-like C subtype was 
the smallest subtype with 13% of the 
discovery cohort and 17% of the validation 
cohort. A small proportion of this subtype 
was BRAF mutant (16%) and 36% were 
dMMR. In this group, all the mesenchymal 
markers excluding FLT1 were considerably 
up-regulated compared to CDH, EGFR, and 
MET (epithelial markers) that were down-
regulated.  Moreover, low proliferative 
activity was recorded in this group. These 
patients had a poor baseline prognosis and 
in addition, were resistant to chemotherapy 
with 5-FU.  In the C-type-MSI patients, only 
50% had 10-year distant metastasis-free 
survival.    
The consensus molecular subtypes of 
colorectal cancer     
At the end of 2015, an international 
consortium published a consensus 
classification for CRC.21 In this major 
collaborative study, the authors evaluated 
the results of the above CRC classifications 
and, by utilizing a network-based approach, 
four robust consensus molecular subtypes 
were identified. The eighteen datasets 
utilized in the above characterization and 
subtyping studies amounted to a cohort 
of 4,151 patients. The authors divided 
the cohort into two equivalent groups for 
training and validation.  
The four consensus subtyping clusters 
comprised 3,104 samples. Additionally, 858 
samples did not fall into any of the subtypes 
and hence were described as unlabelled non-
consensus samples. The clusters were first 
biologically characterized and associated 
with both clinical variables and prognostic 
values. The new taxonomy for CRC is 
described below.
Consensus Molecular Subtype 1 
(CMS1): This subtype was referred to 
as microsatellite instability immune and 
comprised 14% of the cohort. CMS1 had an 
MSI+, CIMP-H, and hypermutated phenotype 
and was highly enriched for BRAF mutants. 
The MSI immune subtype was characterized 
by increased expression of genes associated 
with immune infiltrates together with 
strong activation of the immune evasion 
pathways. Clinically, these tumours were 
frequently diagnosed in females, located on 
the right side, and presented at later stages. 
Furthermore, when compared to the other 
subtypes, CMS1 had a worse survival after 
relapse.
Consensus Molecular Subtype 2 
(CMS2): Thirty-seven per cent of the cohort 
fell in this canonical-epithelial subtype. 
CMS2 had the highest copy number gains 
and copy number losses when compared 
to the other subtypes. Additionally, this 
subtype had high expression of WNT and MYC 
downstream targets. Clinically these tumours 
commonly presented on the left side. In 
contrast to CMS1, patients in this subtype 
had better survival rates after relapse.
Consensus Molecular Subtype 3 
(CMS3): Thirteen per cent of the cohort 
fell into this subtype. The authors referred 
to this as the metabolic subtype on 
account of the metabolic dysregulation that 
characterized the group. The majority of the 
tumours in this subtype were reported to be 
of mixed MSI status, mainly CIMP-L, and had 
a low frequency of copy number alterations.  
Moreover, KRAS mutations were common to 
this particular CMS.        
Consensus Molecular Subtype 4 
(CMS4): This subtype was characterised 
as having prominent transforming growth 
factor-β activation, stromal invasion, 
and angiogenesis. As a consequence, 
this subgroup was also referred to as the 
mesenchymal subtype and comprised 23% 
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of the cohort. CMS4 had a high frequency 
of copy number gains and losses. Clinically, 
tumours in this subtype tended to be 
diagnosed at a later stage and had the worst 
relapse free and overall survival.
Samples with mixed features: 13% of 
the samples did not stratify in any of the 
four consensus molecular subtypes. The 
authors have speculated that the samples 
in this group might be representative of 
either a transition phenotype or intratumoral 
heterogeneity.  
Conclu sion
Molecular classification of colorectal 
cancer is of high significance since the 
colorectal subtypes are useful for generating 
correlations with a number of variables 
namely clinicopathological parameters, 
overall survival, progression free survival, 
and response to treatment and relapse. These 
correlations can facilitate our understanding 
of colorectal cancer biology and provide 
evidence regarding carcinogenesis.9 
Furthermore, these correlations can be 
used to discover new molecular subtypes. 
Moreover, association studies can be helpful 
in highlighting potential confounding factors 
and preventing incorrect associations.9 
Finally, robust molecular classification is 
of paramount importance for the discovery 
and clinical implementation of prognostic 
and predictive biomarkers - the precursors 
for successfully implementation of point 
of care genomics and making personalised 
healthcare a reality.   
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